AINDEX
Markets

Anavex Life Sciences Corp. (AVXL)

AVXLNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)

$1.13

-0.0950 (-7.79%) today

Regular session, Nov 10, 3:40 PM ET

-7.79% 1D
Market cap
$104.28m
P/E
–
EPS, last 4 quarters
$-0.1500
Dividend yield
–
Day range
$1.12 to $1.23
52-week range
$1.07 to $7.60
Average volume
1.09m
Previous close
$1.22

Earnings

next estimate $-0.1100

Next report Nov 24, 2026

Sep 2025

+15.4%

Dec 2025

+40.0%

Mar 2026

–

Jun 2026

+200.0%

estimate reported, and the surprise

Financials

QuarterSep 2025Dec 2025Mar 2026Jun 2026
Revenue––––
Gross profit––––
Operating income-$10.84m-$6.78m-$6.48m$6.74m
Net income-$9.83m-$5.68m-$5.34m$7.82m

News

8 latest

The company

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of central nervous system diseases with high unmet medical need.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-GS
Region
North America
Website
anavex.com

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.